highly significantP < 0.00001
Highly significant differences were observed, with 94% of COVID-19 positive pneumonia patients receiving remdesivir, compared to 46% in the COVID-19 negative pneumonia group ( P < 0.00001).
Highly significant differences were observed, with 94% of COVID-19 positive pneumonia patients receiving remdesivir, compared to 46% in the COVID-19 negative pneumonia group ( P < 0.00001).
Although not statistically significant, there was a trend towards significance in corticosteroid use, with rates 90% of patients in the COVID-19 positive pneumonia group and 76% in the COVID-19 negative pneumonia ( P = 0.062389).